Ultragenyx Pharmaceutical Ownership | Who Owns Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical Ownership Summary
Ultragenyx Pharmaceutical is owned by 106.68% institutional investors, 3.44% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.59% of RARE shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.65% of its assets in Ultragenyx Pharmaceutical shares.
RARE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Ultragenyx Pharmaceutical | 106.68% | 3.44% | -10.12% |
| Sector | Healthcare Stocks | 244.37% | 12.11% | -156.48% |
| Industry | Biotech Stocks | 379.01% | 11.75% | -290.76% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 10.65M | 10.59% | $355.75M |
| Vanguard group | 10.26M | 10.29% | $236.07M |
| Rtw investments, lp | 7.80M | 7.75% | $260.34M |
| Blackrock | 5.60M | 6.65% | $230.30M |
| Aqr capital management | 6.56M | 6.52% | $214.14M |
| State street | 6.16M | 6.12% | $205.64M |
| Vanguard capital management | 4.30M | 4.27% | $143.46M |
| Two sigma investments, lp | 3.62M | 3.60% | $120.91M |
| Sands capital management | 3.16M | 3.14% | $105.46M |
| Jacobs levy equity management | 2.94M | 2.92% | $98.16M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Cutter capital management, lp | 406.80K | 7.01% | $17.11M |
| Krensavage asset management | 390.88K | 4.96% | $13.05M |
| Eagle health investments lp | 884.12K | 4.89% | $29.52M |
| Sofinnova investments | 1.72M | 2.96% | $57.35M |
| Bioimpact capital | 1.42M | 2.89% | $47.35M |
| Palo alto investors lp | 596.50K | 2.75% | $19.92M |
| Sphera funds management | 588.49K | 2.56% | $19.65M |
| Rtw investments, lp | 7.80M | 2.22% | $260.34M |
| B group | 135.00K | 2.12% | $4.51M |
| Privium fund management b.v. | 338.80K | 2.08% | $11.31M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Rtw investments, lp | 7.80M | 2.22% | 4.15M |
| Blackrock funding, inc. /de | 10.65M | 0.01% | 3.35M |
| Aqr capital management | 6.56M | 0.07% | 1.98M |
| Jacobs levy equity management | 2.94M | 0.35% | 1.51M |
| Bioimpact capital | 1.42M | 2.89% | 1.42M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Baker bros. advisors lp | - | - | -2.77M |
| Assenagon asset management | 120.86K | 0.01% | -2.14M |
| Suvretta capital management | - | - | -2.02M |
| Citadel advisors | 210.53K | 0.00% | -1.90M |
| Alkeon capital management | - | - | -1.69M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Bioimpact capital | 1.42M | 2.89% | 1.42M | $47.35M |
| Sixth street partners management company | 760.04K | 0.00% | 760.04K | $25.38M |
| Braidwell lp | 588.70K | 0.53% | 588.70K | $17.71M |
| Panagora asset management | 586.23K | 0.06% | 586.23K | $19.57M |
| Axa investment managers | 417.20K | 0.03% | 417.20K | $12.55M |
Sold Out
| Holder | Change |
|---|---|
| Stephens consulting | -1.00 |
| Dunhill financial | -1.00 |
| Tfc financial management | -2.00 |
| Concourse financial group securities | -3.00 |
| Twin peaks wealth advisors | -3.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 325 | 4.17% | 107,318,416 | 9.39% | 106 | 1.12% | 178 | -5.82% | 98 | 20.99% |
| Mar 31, 2026 | 174 | -45.63% | 39,598,739 | -57.85% | 40 | 0.44% | 99 | -42.77% | 51 | -43.96% |
| Dec 31, 2025 | 197 | -40.66% | 57,538,166 | -39.74% | 57 | 0.61% | 105 | -42.62% | 60 | -36.84% |
| Sep 30, 2025 | 316 | -7.87% | 91,125,125 | -3.19% | 92 | 1.01% | 174 | -2.79% | 92 | -9.80% |
| Jun 30, 2025 | 338 | 6.29% | 94,259,190 | 8.19% | 95 | 1.17% | 178 | 10.56% | 100 | -2.91% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.60M | 3.65% | 8.27K |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.00M | 3.05% | 14.92K |
| Vanguard US Total Market Shares ETF | 2.81M | 3.04% | 92.60K |
| Vanguard Total Stock Mkt Idx Inv | 2.99M | 3.03% | 30.79K |
| Vanguard Morn Total Stk Mkt Idx Investor | 2.99M | 3.03% | 30.79K |
| iShares Russell 2000 ETF | 2.45M | 2.48% | -43.49K |
| Vanguard Small Cap Index | 2.14M | 2.18% | -2.21K |
| Sands Capital Select Growth TE Inst EQ | 1.99M | 2.02% | 53.79K |
| JPMorgan Mid Cap Growth I | 1.59M | 1.65% | -10.19K |
| JPM US Mid Cap Growth-Composite | 1.59M | 1.65% | -37.19K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 03, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | $47.35K |
| Aug 03, 2026 | Horn Howard | Chief Financial Officer | Sell | $117.02K |
| Jul 01, 2026 | Horn Howard | Chief Financial Officer | Sell | $155.64K |
| Jun 15, 2026 | Sanders Corazon (Corsee) D. | - | Sell | $50.10K |
| Jun 15, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | $46.75K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 3 |
| 2026 Q2 | - | 7 |
| 2026 Q1 | - | 13 |
| 2025 Q4 | - | 3 |
| 2025 Q3 | - | 3 |
RARE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools